|
Joseph Alan Bauer, Ph.D. Bauer Research Foundation Akron Innovation Campus 411 Wolf Ledges Pkwy, Suite 105 Akron, Ohio 44311 Phone: 330-972-2748 Email: jabauer@bauerresearch.org www.brf.vpweb.com |
|
Background The Bauer Research Foundation (BRF) was established to promote the humane treatment of pets affected with cancer. We are committed to promoting the health and well-being of animals and strengthening the human-animal bond as part of a total wellness paradigm. Our maxim is “Strengthening the human-animal bond.” June 2009– Case study in dogs http://www.springerlink.com/content/a1224t6u5364n257/ My work has resulted in three United States Patents (one pending) and over twenty-five foreign patents which pertain to these compounds. Specifically, I developed a nitric oxide donor, nitrosylcobalamin (NO-Cbl) based on vitamin B12, that functions as a “Trojan Horse.” Animal experiments have shown that NO-Cbl preferentially targets cancer cells with minimal side effects to non-malignant cells. This research work was recently featured in the Cleveland Clinic Magazine in an article about “Smart Medicine” as well as the 2006 Annual Report of the Cleveland Clinic. http://gozips.uakron.edu/~jbauer/summary 08.pdf The BRF is working to provide NO-Cbl for research use only. The Bauer Research Foundation is located on the Akron Innovation Campus. 411 Wolf Ledges Pkwy, Suite 105, Akron, Ohio 44311. http://www.uakron.edu/research/aic.dot |
|
In 2003, the National Cancer Institute’s Center for Cancer Research (CCR) launched the Comparative Oncology Program (COP) http://ccr.cancer.gov/resources/cop/ to help researchers better understand the biology of cancer and to improve the assessment of novel treatments for humans by treating pet animals-primarily cats and dogs-with naturally occurring cancer, giving these animals the benefit of cutting-edge research and therapeutics. Spontaneous cancers in dogs and cats are an underused group of naturally occurring malignancies that share many features with human cancers. |
|
Education
The University of Akron, Akron, OH Ph.D. - Chemistry, December 1999 Concentration in Biochemistry/polymer science and Biomedical Research. Dissertation: http://gozips.uakron.edu/~jbauer/dissertation.pdf Walsh University, North Canton, OH B.A. - Bachelor of Business Administration - Accounting, May 1994 Major in accounting and a minor in chemistry. |
|
Experience
The Cleveland Clinic Foundation, Cleveland, OH Staff Scientist – 9/2007- 12/2008 Center for Hematology & Oncology Molecular Therapeutics I was responsible for drug design and development of novel drugs with an emphasis on targeted drug-delivery. My fields of specialization included signal transduction pathways/apoptosis, cobalamin chemistry, molecular biology, oncology research, and the biochemistry of nitric oxide. I worked with many leaders in the oncology community to strengthen the focus and presentation of my research. I actively pursued grant funding and collaborated with several intra-institutional and national research laboratories. I published in high-profile international scientific journals and give many presentations yearly tailored for a variety of audiences. Research Associate Staff – 11/2000 – 9/2007 Center for Hematology & Oncology Molecular Therapeutics Research Fellow - Immunology 10/1999-10/2000 I was a post-doctoral fellow in the Immunology Department. I learned and practiced many molecular biology techniques in my research project which focused on the role of NFAT in IFNAR1 signaling. Walsh University, North Canton, OH Adjunct Associate Professor 9/1996-9/1999 I taught several courses after becoming a Ph.D. candidate. These courses included: GOBC I and II. Principles of Chemistry Lab I and II, and Organic Chemistry Lab I and II. The University of Akron, Akron, OH Graduate Assistant/Researcher 8/1994-10/1999 I was a graduate student pursuing my doctorate in Chemistry. My research focused on the biochemistry of nitric oxide, chemotherapeutic drug design, diabetes research, wound healing research, invasive/non-invasive surgical procedures, polymer synthesis/controlled release studies, and animal studies using rats and mice. My graduate research experience resulted in the publication of five peer-reviewed research articles and a United States Patent. United National Bank & Trust Co. (UNIZAN Bank), Canton, OH Assistant Trust Administrator 9/1991-8/1994 While attending Walsh University, I worked in the Trust Department's Employee Benefits section. I was responsible for the maintenance of various employee benefit trusts which included 401(k), MPP plans, PSP plans, and pension plans. I was proficient in financial analysis software, Lotus, Excel. I prepared monthly income statements, profit/loss allocations and year-end projections. |
|
Fields of Specialization à Signal transduction pathways; apoptosis assays à Cobalamin chemistry à Growth assays to assess anti-tumor agents à Biological response therapy using interferons and Apo2L/TRAIL à Tissue culture à Biochemistry of nitric oxide à Chemotherapeutic drug design à Pharmacokinetics/Pharmacodynamics à Molecular biology (EMSA, RPA, Western blots) à Diabetes research à Wound healing research à Immunohistochemistry à Invasive/non-invasive surgical procedures à Polymer synthesis/controlled release studies à Animal studies using mice, rats and dogs |
|
Patents U.S. Patent Pending 20080138280 Bauer J.A. Composition and methods for inhibiting cell survival. 2008. http://gozips.uakron.edu/~jbauer/20080138280.pdf U.S. Patent # 6,752,986 Bauer, J.A. and Lindner, D.J.: Composition and methods for affecting metallocorrinoid uptake. 2001 http://gozips.uakron.edu/~jbauer/bauer comp.pdf U.S. Patent # 5,936,082 Bauer, J.A.: Metallocorrinoids as biologically compatible carriers of pharmacological agents. August 10, 1999. http://gozips.uakron.edu/~jbauer/5936082.pdf |
|
Professional Associations 2009 – present, Veterinary Cancer Society 2004 - Present, Nitric Oxide Society, Member 2001 – Present, American Association for Cancer Research, Associate member 1999 – Present, American Chemical Society, Member Honors/Awards Honors: 1996 -1997 Research fellowship, IMSCO, Inc. (Boston, MA) Research grant $107,000, The University of Akron, (Investigator) 1998, 1999 BFGoodrich Collegiate Inventors Award Semi-Finalist 2000- 2001: House Staff Association Committee Member 2000 Ethicon Endosurgery: Young Investigator’s Award– Breast Cancer Research, $10,000 2004 Cleveland Clinic Foundation Innovator Award 2001, 2003-2006, 2008 American Cancer Society, Silber Fellowship Award Sponsor Support: 2000 CCF Innovations Support Grant, $25,000 (Principal Investigator) 2001 American Cancer Society, $20,000 (Co-principal investigator) 2004 NCI: 1R01CA098536-01A1 “Nitrosylcobalamin – a novel chemotherapeutic agent”, $1.2 million, (Co-investigator) 2004 Reuter Foundation, $30,000 (Principal Investigator) 2004 Mareb Foundation, $75,000 (Principal Investigator) 2005 Mareb Foundation, $75,000 (Principal Investigator) 2005 Charles R. Jelm Foundation, $15,000 (Principal Investigator) 2006 NCI/RAID “Nitrosylcobalamin (NO-Cbl, NSC D720947): A vitamin B12 based anti-tumor agent (Principal Investigator) 2006 Reuter Foundation, $12,000 (Principal Investigator) 2007 CCF Innovation Validation Fund, “Evaluation of oral delivery of nitrosylcobalamin: assessment of pharmacokinetics/pharmacodynamics” $47,500 (Principal Investigator) 2008 Valley Save-a-Pet $5,000 (Principal Investigator) 2008 Reuter Foundation, $35,000 (Principal Investigator) Presentations 1. Bauer JA: Biochemistry of Nitric Oxide Donors: Therapy vs. Toxicity. The Johns Hopkins University School of Medicine - Department of Oncology, Breast Cancer Research Division, Baltimore, MD. June 16, 1999. 2. Bauer JA, Grane RW, Jacobs B, Morrison BH, Borden EC, Lindner DJ. IFN-a2 and Peg-IFN-a2 Inhibit Tumor Induced Angiogenesis in the Murine Dermis Model. Annual Meeting of the International Society for Interferon and Cytokine Research, Cleveland, OH October 7-11, 2001. 3. Gamero AM, Bauer JA, Larner AC: The Transcription factor NFAT participates in type I IFN receptor signaling. Annual Meeting of the International Society for Interferon and Cytokine Research, Cleveland, OH October 7-11, 2001. 4. Morrison BH, Bauer JA, Grane RW, Ozdemir AM, Chawla-Sarkar M, Lindner DJ. Inositol Hexakisphosphate Kinase 2 Sensitizes Ovarian Carcinoma Cells to Gamma-Irradiation. Annual Meeting of the International Society for Interferon and Cytokine Research, Cleveland, OH October 7-11, 2001. 5. Morrison BH, Bauer JA, Lindner DJ. Regulator of Interferon-Induced Death-2 Sensitizes Ovarian Carcinoma Cells to Gamma Irradiation. Proceedings of the American Association for Cancer Research 42:667, New Orleans, LA March 2001. 6. Bauer JA, Morrison BH, Grane RW, Jacobs BS, Dabney S, Gamero AM, Carnevale KA, Smith DJ, Drazba J, Seetharam B, Lindner DJ. Nitrosylcobalamin: a novel chemotherapeutic agent. Proceedings of the American Association for Cancer Research 43:1016, San Francisco CA March 2002. 7. Bauer JA, Morrison BH, Oates R, Lee P, Borden E, Lindner DJ. Angiozyme and interferon-a2b synergistically inhibit tumor angiogenesis. Proceedings of the American Association for Cancer Research 44:1159, Washington, DC July 2003. 8. Taylor KL, Bauer JA, Morrison BH, Oates R, Grane RW, Jacobs BS, Lindner DJ, Borden EC. Interferon-a2b inhibits endothelial cell capillary network formation in vitro and tumor induced angiogenesis in vivo. Proceedings of the American Association for Cancer Research 44:1150, Washington, DC July 2003. 9. Lupica JA, Bauer JA, Chawla-Sarkar M, Morrison BH, Tang Z, Oates RK, Almasan A, DiDonato JA, Borden EC, Lindner DJ. Effects of nitrosylcobalamin on NF-κ B survival signaling and antitumor activity of Apo2L/TRAIL. Proceedings of the American Association for Cancer Research 45:5580, Orlando, FL March 2004. [Mini-symposium: speaker Bauer] 10. Morrison BH, Tang Z, Jacobs BS, Bauer JA, Lindner DJ. Intracellular translocation of Inositol Hexakisphosphate Kinase 2 during IFN-b- or radiation-induced apoptosis. Proceedings of the American Association for Cancer Research 45:4129, Orlando, FL March 2004. 11. Bauer JA. From the bench top to the bedside: Overcoming obstacles in cancer drug development. Annual Meeting of the American Cancer Society. Beechwood, Ohio. April 2004. [invited speaker] http://gozips.uakron.edu/~jbauer/ACS 2004 keynote.pdf 12. Bauer JA: Relay for Life, Ambassador: Targeting tumors with nitrosylcobalamin, Mill Ridge Relay, North Royalton, Ohio June 11, 2004. [invited speaker] 13. Bauer JA: Relay for Life Ambassador: Targeting tumors with nitrosylcobalamin, Green, Ohio June 25, 2004. [invited speaker] 14. Bauer JA: NO-Cbl inhibits IKK and NF-kB. 8th Annual meeting of the Regional Cancer Center Consortium for the Biological Therapy of Cancer, Hershey, PA February 2005. [invited speaker] 15. Lupica JA , Bauer JA, Chawla-Sarkar M, Morrison BH, Tang Z, Oates RK, Almasan A, DiDonato JA, Borden EC, Lindner DJ. Effects of nitrosylcobalamin on NF-κ B survival signaling and antitumor activity of Apo2L/TRAIL. American Chemical Society, Meeting-in-Miniature, Baldwin Wallace College, Berea, OH, March 2005. http://gozips.uakron.edu/~jbauer/bauer layout 98659.pdf 16. Bauer JA, Morrison BH, Tang Z, Oates RK, Lupica JA, Anderson CR, Poulson JM, Gieg J, Borden EC, Lindner DJ. In vivo anti-tumor effects of nitrosylcobalamin (NO-Cbl) against canine carcinomas: two case studies. Proceedings of the American Association for Cancer Research 46:471, Anaheim, CA April 2005. http://gozips.uakron.edu/~jbauer/05AACR.pdf 17. Morrison BH, Tang Z, Jacobs BS, Bauer JA, Lindner DJ. IHPK2 sensitizes ovarian carcinoma to IFN-α2-induced apoptosis. Proceedings of the American Association for Cancer Research 46:2705, Anaheim, CA April 2005. 18. Morrison BH, Tang Z, Bauer JA, Lindner DJ. IHPK2-TRAF2 binding promotes apoptosis. Cell Research 15 (10): 171, Shanghai, China October 2005. 19. Tang Z, Bauer JA, Morrison BH, Lindner DJ. Nitrosylcobalamin Promotes Cell Death via S-Nitrosylation of apo2L/TRAIL Receptor DR4. Proceedings of the American Association for Cancer Research, Washington, DC April 2006. http://gozips.uakron.edu/~jbauer/06AACR.pdf 20. Bauer JA. Anti-tumor effects of nitrosylcobalamin. Northeastern Ohio Universities College of Medicine (NEOUCOM), Rootstown, OH. May 2006. [invited speaker] 21. Lupica JA, Bauer JA, Tang Z, Lindner DJ, DiDonato DJ. Exogenous nitric oxide donors exhibit differential inhibition of NF-kB survival signaling dependent on strong vs. weak kinetic activators. Nitric Oxide Society: Biology, Chemistry and Therapeutic Applications of Nitric Oxide. Monterey, CA. Nitric Oxide 14(4): 53, June 2006. http://gozips.uakron.edu/~jbauer/Lupica Bauer NO 2006.pdf 22. Morrison B, Bauer J, Tang Z, Lupica J and Lindner D. The Role of Inositolhexakisphosphate Kinase 2 in TNF-a Signal Transduction. European Cytokine Network, Special issue “Cytokine 2006”, 17:25, 6th Joint Meeting of the International Cytokine Society, International Society for Interferon and Cytokine Research, European Cytokine Society, Vienna, Austria, August 2006. 23. Schade AE, Szpurka H, Jankowska A, Bauer JA., Hsi E D et al. Interdiction of Src Family Kinase Activity as a Therapeutic Option for Aberrant JAK-STAT Signaling: Potential Targeted Therapy of JAK2 V617F in Myeloproliferative Disorders with Currently Available Kinase Inhibitors. American Society of Hematology, Orlando, Florida, December 2006. 24. Lupica JA, Bauer JA, Tang Z, Lindner DJ, DiDonato DJ. Exogenous nitric oxide donors exhibit differential inhibition of NF-kB survival signaling dependent on strong vs. weak kinetic activators. 10th Annual meeting the Regional Cancer Center Consortium for the Biological Therapy of Cancer, Cleveland, Ohio February 2007. Received Best Poster award. 25. Bauer JA, Lupica JA, Morrison BH, Schmidt H, Tang Z, Haney R, Oates RK, Lee RM, DiDonato JA, Lindner DJ: Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling. Proceedings of the American Association for Cancer Research, Los Angeles California, April 2007. http://gozips.uakron.edu/~jbauer/2007 AACR.pdf 26. Bauer JA: Nutritional based anti-tumor therapy: Designing a “Trojan Horse” for the targeted destruction of tumor cells. Magnificat High School, Cleveland, Ohio, May 2007. [invited speaker]. 27. Bauer JA, Lindner DJ, Yadav SP: Comparative kinetics and affinity analyses between vitamin B12 analogs and intrinsic factor. 2nd Annual Developments in Protein Interaction Analysis (DiPIA), Phoenix, Arizona, May 2007. http://gozips.uakron.edu/~jbauer/07DIPIA.pdf 28. Morrison BH, Lorenz RR, Lee WT, Teker AM, Scharpf J, Strome M,Nallar SC, Kalvakolanu D, Bauer JA, Lindner DJ: Somatic mutations of inositol hexakisphosphate kinase 2 in tumors of head and neck squamous cell carcinoma patients. Journal of Interferon & Cytokine Research 27(8):704, Annual Meeting of the International Society for Interferon and Cytokine Research, Oxford, England, September 16-19, 2007. 29. Medvetz DA, Hindi KM, Panzner MJ, Ditto AJ, Yun Y, Ogrich LM, Bauer JA, Lindner DJ, Youngs WJ: Synthesis, characterization and antitumor activity of N-heterocyclic carbene silver acetate complexes. Proceedings of the American Association for Cancer Research, San Diego California, April 2008. 30. Bauer JA, Ogrich LM, Lee RM, Haney RM, Morrison BH, Lupica JA, Cutter J, Bennani-Baiti N, DiDonato JA, Vogelbaum MA, Lindner DJ: Treating CNS tumors with nitrosylcobalamin: Improving upon Apo2L/TRAIL, radiation, and temozolomide therapies. Proceedings of the American Association for Cancer Research, San Diego, California, April 2008. http://gozips.uakron.edu/~jbauer/08AACR.pdf 31. Bauer JA, Frye G, Bahr A, Gieg J, DJ Lindner. Anti-tumor effects of nitrosylcobalamin (NO-Cbl) against spontaneous tumors in dogs. Genes Dogs and Cancer: 5th International Canine Cancer Conference, February 2009. Orlando, Florida. 32. Bauer JA, Frye G, Bahr A, Gieg J, DJ Lindner. Anti-tumor effects of nitrosylcobalamin (a vitamin B12-based nitric oxide adduct) against spontaneous cancer in dogs. 237th American Chemical Society National Meeting & Exposition. Salt Lake City, UT. March 2009. [invited speaker]. 33. Bauer JA: Nutritional based anti-tumor therapy: Designing a “Trojan Horse” for the targeted destruction of tumor cells. Western University Health Sciences Center, Pomona, CA April 2009. [invited speaker]. 34. Bauer JA, Frye G, Bahr A, Gieg J, DJ Lindner. Anti-tumor effects of nitrosylcobalamin (NO-Cbl) against spontaneous tumors in dogs. 100th Annual meeting of the American Association for Cancer Research. Denver, Colorado April 2009. http://gozips.uakron.edu/~jbauer/2009 AACR.pdf 35. Ogrich LM, Garber CM, Bauer JA, Sielski S, Haney RM, Hindi K, Knapp A, Panzner M, Youngs WJ, Lindner DJ. Antitumor effects of N-heterocylic carbene silver acetate complexes compared to cisplatin, carboplatin and oxaliplatin. 100th Annual meeting of the American Association for Cancer Research. Denver, Colorado. April 2009. http://gozips.uakron.edu/~jbauer/SCC5 2009.pdf |
|
Editorial Contributions
Academic Editor, Public Library of Science (PLoS ONE) January 2008 – present www.plosone.org Invited Editorial Reviews Journal of the American Chemical Society Molecular Cancer Therapeutics Cancer Research Clinical Cancer Research
|
|
Press Releases 1. Cleveland Clinic Researchers Find Promise in B-12 Chemotherapy, July 2002 http://www.lerner.ccf.org/news/archived/20020701.php 2. B12 as Carrier of Anticancer Drug: Nitric oxide. July 2002 http://www.annieappleseedproject.org/b12ascarofan.html 3. Researchers Find Promise in B-12 Chemotherapy: Targeted drug therapy using cobalamin, or vitamin B-12, is the carrier of a cancer-killing agent. August 2002 http://www.eclevelandclinic.org/newsLetter.jsp?display=/static-html/newsletter/news/2002/B12.html 4. Cleveland Clinic, Ricerca Biosciences to Collaborate on Development of Cancer-Fighting Drug. January 2004 http://www.globeinvestor.com/servlet/ArticleNews/print/PRNEWS/20040126/2004_01_26_11_5455_1078220 5. Modified vitamin B12 shuttles lethal cargo to tumors March 2004 http://www.cancerpage.com/news/article.asp?id=6923 6. Researchers find new purpose for existing drugs to suppress colon cancer metastasis, secure post-radiation brain function, and trick tumors. March 2004 http://www.news-medical.net/print_article.asp?print=yes&id=213 7. Existing Therapies Applied to New Use in Broader Spectrum of Cancer Care March 2004 http://www.eurekalert.org/pub_releases/2004-03/aafc-eta032604.php 8. B12 influences NF-kB survival signaling and antitumor activity of Apo2L/TRAIL April 2004 http://www.obgyn.net/newsheadlines/headline_medical_news-Cleveland_Clinic-20040419-1.asp 9. Smart Medicine: targeting cancer inside and out. January 2005 (Winter 2005 issue) www.clevelandclinic.org/clevelandclinicmagazine/pdf/winter_05.pdf 10. Annual Report- Cleveland Clinic Foundation 2006 www.clevelandclinic.org/aboutus/pdf/CCAR2006.pdf RESEARCH: Cleveland Clinic Cancer Center researchers developed a new cancer drug that disguises itself as vitamin B-12 to trick cancer cells into accepting nitric oxide, a powerful cancer killer. The drug, called nitrosylcobalamin, is so promising that the National Cancer Institute is fast-tracking its development through its Rapid Application to Development program – the only new drug from anywhere so honored in 2006. 11. Nitrosylcobalamin acts as "Trojan horse" to target cancer cells, Reuters 2009 http://www.rtmagazine.com/reuters_article.asp?id=20090325scie005.html 12. Tales of the “Trojan horse drug” and the “miracle dogs” ACS 2009 13. 'Miracle Dog' Beats Aggressive Cancer, WebMD 2009 http://www.webmd.com/cancer/news/20090323/miracle-dog-beats-aggressive-cancer 14. Dogs Help in Hunt for New Cancer Drugs, Forbes 2009 http://www.forbes.com/feeds/hscout/2009/03/23/hscout625332.html US News & World Report, 2009 MSN Health 2009 http://health.msn.com/health-topics/cancer/articlepage.aspx?cp-documentid=100235078 15. Canine Cancer: Novel Treatment Options 2009 http://landofpuregold.com/cancer/novel.htm References 1. Dr. Ronald Bukowksi, Director Experimental Therapeutics Program, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Ave. Cleveland Ohio 44195. Email: bukowsr@ccf.org 2. Robert L. Lintz, Board of Trustees Cleveland Clinic; Retired Plant Manager, Parma Metal Fabricating Plant, General Motors Corporation. Email: ispartan62@aol.com 3. Robert Reuter, CEO Dylon Industries, President, The Reuter Foundation, mail@ReuterFdn.org 4. Dr. Michael J. Dunphy, Chairman Department of Chemistry, Walsh University, 2020 East Maple Street NW, North Canton, Ohio 44720. Email: dunphy@mikedunphy.com 5. Dr. Joseph Jankowski, Assistant Vice President - Biomedical Sciences, Case Western Reserve University, Cleveland Ohio 44106. Email: jxj44@cwru.edu 6. Dr. Daniel J. Lindner, Cleveland Clinic, Director Animal Tumor Core, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, Ohio 44195. Email: lindned@ccf.org Reference letter: http://gozips.uakron.edu/~jbauer/lindner rec letter0001.pdf DISCLAIMER The information contained in this website is intended to supplement, not substitute for, the expertise and judgment of your veterinarian. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that the use of NO-Cbl in treating your pet is safe, appropriate or effective. NO-Cbl has not been approved or tested by the Food and Drug Administration or the Center for Veterinary Medicine. |
|
Patents and Publications Research Articles 1. Bauer, J.A.: Synthesis, characterization, and nitric oxide release profile of nitrosylcobalamin: a potential chemotherapeutic agent. AntiCancer Drugs. 1998; 9(3): 239-244. http://gozips.uakron.edu/~jbauer/Anti cancer drugs 1998.pdf 2. Bauer, J.A.: Hydroxocobalamins as biologically compatible donors of nitric oxide implicated in the acceleration of wound healing. Med. Hypotheses. 1998; 51(1): 65-67. 3. Bauer, J.A.: The urea cycle as a source of nitric oxide implicated in the pathogenesis of insulin-dependent diabetes mellitus. Med. Hypotheses. 1998; 51(1): 71-73. 4. Bauer, J.A., Rao, W., Smith, D.J.: Evaluation of linear polyethyleneimine/nitric oxide adduct on wound repair: therapy versus toxicity. Wound Repair Regen. 1998; 6(6): 569-577. 5. Bauer, J.A., Harr, M.E., Smith, D.J.: Diminished nitric oxide production following administration of transforming growth factor-beta 1 using a noninflammatory wound repair model. Nitric Oxide. 1999; 3(5): 402-408. 6. Morrison BH, Bauer JA, Kalvakolanu DV, Lindner DJ. Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells. J Biol Chem 2001;276:24965-70. 7. Morrison BH, Bauer JA, Hu J, Grane RW, Ozdemir AM, Chawla-Sarkar M, et al. Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics. Oncogene 2002;21:1882-9. 8. Bauer JA, Morrison BH, Grane RW, Jacobs BS, Dabney S, Gamero AM, Carnevale KA, Smith DJ, Drazba J, Seetharam B, Lindner DJ: Effects of interferon-beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin. Journal of the National Cancer Institute. 2002; 94: 1010-1019. http://gozips.uakron.edu/~jbauer/JNCI1010.pdf 9. Bauer JA, Morrison BH, Borden EC, Lindner DJ. Interferon alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis. Journal of Interferon and Cytokine Research 2003; 23: 3-10. 10. Bauer JA et al. Suppression of NF-kB survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. Journal of Biological Chemistry. 2003; 278: 39461-39469. http://gozips.uakron.edu/~jbauer/Bauer JBC 2003.pdf 11. Morrison BH, Tang Z, Jacobs BS, Bauer JA, Lindner DJ. Apo2L/TRAIL induction and nuclear translocation of inositol hexakisphosphate kinase 2 during IFN-b-induced apoptosis in ovarian carcinoma. Biochem J .2005; 385:595-603. 12. Tang Z, Bauer JA, Morrison BH, Lindner DJ. Nitrosylcobalamin promotes cell death via S-nitrosylation of Apo2L/TRAIL receptor DR4. Molecular and Cellular Biology 2006; 26(15):5588-94. http://gozips.uakron.edu/~jbauer/Tang 2006 MCB.pdf 13. Morrison BH, Bauer JA, Lupica JA, Tang Z, Schmidt H, DiDonato JA, Lindner DJ Effect of inositol hexakisphosphate kinase on Tak1 and NF-kB activation. Journal of Biological Chemistry 2007; 282(21): 15349-56. 14. Bauer JA, Lupica JA, Schmidt H, Morrison BH, Haney RM, Masci RK, Lee RM, DiDonato JA, Lindner DJ: Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling. PLoS ONE 2007 2: e1313 http://gozips.uakron.edu/~jbauer/PLOSONE bauer 2007.pdf 15. Ahuja R, Yammani R, Bauer JA, Kalra S, Seetharam S, Seetharam B: Interactions of cubilin with megalin and the product of amnionless gene (AMN): Effect on its stability. Biochem J. 2008; 410 (2):301-8. http://gozips.uakron.edu/~jbauer/Seetharam 2008.pdf 16. Bauer JA, Frye, G, Bahr A, Gieg J, Brofman P: In vivo anti-tumor effects of nitrosylcobalamin (NO-Cbl) against anal sac adenocarcinoma: a case study. 2009 Invest New Drugs http://gozips.uakron.edu/~jbauer/Invest New Drugs 2009.pdf |
